| abstract |
Inhibitory oligonucleotides are described having the general formula (I) that can be used in pharmaceutical compositions, whereby in formula (I) C is cytidine or a derivative thereof, where this cytidine derivative is selected from the group consisting of 5-methylcytidine, a cytidine-like nucleotide, having a chemical modification affecting the cytosine base, cytidine nucleoside sugar, or both cytosine base and cytidine nucleoside sugar, 2'-O-methylcytidine, 5-bromocytidine, 5-hydroxycididine, ribocytidine and cytosine-P-D- arabinofuranoside, G is guanosine or a derivative thereof, where this guanosine derivative is selected from the group consisting of 7-diazaguanosine, guanosine-like nucleotide having a chemical modification affecting the guanosine base, guanosine X nucleoside sugar, or guanosine X nucleoside, and any nucleotide sequence with 0-12 bases, and each nucleotide depends on any other, X is any nucleotide sequence having 0-3 nucleotides, N and N are each depending on any nucleotide, N and N are pyrimidine or a modified pyrimidine, N and N are pyrimidine or a modified pyrimidine, N is purine or a modified purine, N is a modified pyrimidine, A or a modified purine, where at least two of the nucleotides N, N, N or N are modified pyrimidines. |